Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol

Hotel Dieu de France Hospital100 enrolled

Overview

Randomized study. Patients with coronary artery disease equivalent will be randomized to receive atorvastatin 40 mg/day + placebo vs. atorvastatin 40 mg/day + ezetimibe 40 mg/day. Oxidized LDL cholesterol will be measured at baseline and after 8 weeks of treatment. Hypothesis is that ezetimibe will lower oxidized LDL

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

100

Conditions

Coronary Artery Disease Diabetes

Interventions

ezetimibeDRUG

Patients will receive 10 mg/day of ezetimibe for 8 weeks

Eligibility

Sex: ALLMin age: 21 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * CAD or CAD equivalent Exclusion Criteria: * Prior CABG or PCI within 3 months Prior use of ezetimibe within 3 months Receiving atorvastatin 40 mg/day or 80 mg/day or any dose of rosuvastatin CHF NYHA stage \>2 Creatinin clearance \< 30 ml/min

Locations (1)

Hotel Dieu de France Hospital

El Achrafiyé, Beirut, Lebanon

Outcomes

Primary Outcomes

level of oxidized LDL cholesterol at end of study

Time frame: 8 weeks of treatment

Secondary Outcomes

small dense LDL level

Time frame: 8 weeks of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.